1-2 of 2
Paul G. Kluetz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development

Available to Purchase
Joshua M. Donaldson, Marjilla Seddiq, Michael J. Fusco, Shyamli Singla, Gulsum E. Pamuk, Rosa J. Lee-Alonzo, Bronwyn D. Mixter, Kirsten B. Goldberg, Laleh Amiri-Kordestani, R. Angelo de Claro, Nicole Drezner, Nicole J. Gormley, Bindu Kanapuru, Steven J. Lemery, Lola A. Fashoyin-Aje, Nicholas C. Richardson, Harpreet Singh, Daniel L. Suzman, Marc R. Theoret, Paul G. Kluetz, Richard Pazdur
Journal: Cancer Discovery
Cancer Discov (2023) 13 (12): 2515–2524.
https://doi.org/10.1158/2159-8290.CD-23-1226
Published: 12 December 2023
View articletitled, Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development
Open the PDF for Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development in another window
Journal Articles

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Free
Keith T. Flaherty, James H. Doroshow, Susan Galbraith, Antoni Ribas, Paul G. Kluetz, Richard Pazdur, Marc R. Theoret
Journal: Cancer Discovery
Cancer Discov (2021) 11 (8): 1881–1885.
https://doi.org/10.1158/2159-8290.CD-21-0850
Published: 01 August 2021
View articletitled, Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective
Open the PDF for Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective in another window